Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.

[1]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[2]  Lipsky Pe.  Role of cyclooxygenase-1 and -2 in health and disease. , 1999 .

[3]  J. Wallace,et al.  Limited anti‐inflammatory efficacy of cyclo‐oxygenase‐2 inhibition in carrageenan‐airpouch inflammation , 1999, British journal of pharmacology.

[4]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Lipsky.  Role of cyclooxygenase-1 and -2 in health and disease. , 1999, American journal of orthopedics.

[6]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[7]  C. Bruni,et al.  Helicobacter pylori Up-regulates Cyclooxygenase-2 mRNA Expression and Prostaglandin E2 Synthesis in MKN 28 Gastric Mucosal Cells in Vitro * , 1998, The Journal of Biological Chemistry.

[8]  J. Pepper,et al.  Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. , 1998, Biochemical and biophysical research communications.

[9]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[10]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[11]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[12]  E. Uhl,et al.  Expression of mRNA for Phospholipase A2, Cyclooxygenases, and Lipoxygenases in Cultured Human Umbilical Vascular Endothelial and Smooth Muscle Cells and in Biopsies from Umbilical Arteries and Veins , 1998, Journal of Vascular Research.

[13]  A. Quyyumi,et al.  Aspirin improves endothelial dysfunction in atherosclerosis. , 1998, Circulation.

[14]  Terry J. Smith,et al.  Cutting Edge: CD40 Engagement Up-Regulates Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Lung Fibroblasts , 1998, The Journal of Immunology.

[15]  B. Graf,et al.  CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. , 1998, Journal of immunology.

[16]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[17]  P. Libby,et al.  Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.

[18]  J. Pepper,et al.  Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Libby,et al.  Ligation of CD40 Activates Interleukin 1β-converting Enzyme (Caspase-1) Activity in Vascular Smooth Muscle and Endothelial Cells and Promotes Elaboration of Active Interleukin 1β* , 1997, The Journal of Biological Chemistry.

[20]  P. Libby,et al.  Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.

[21]  R. Thompson,et al.  Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. , 1997, Journal of vascular surgery.

[22]  P. Libby,et al.  Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1997, Nature.

[24]  R. DuBois,et al.  Prostaglandin endoperoxide synthase: why two isoforms? , 1996, The American journal of physiology.

[25]  H. Jacobson,et al.  Functional and molecular aspects of renal prostaglandin receptors. , 1996, Journal of the American Society of Nephrology : JASN.

[26]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[27]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[28]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[29]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[30]  D. Reed,et al.  Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Otto,et al.  Different Intracellular Locations for Prostaglandin Endoperoxide H Synthase-1 and −2 (*) , 1995, The Journal of Biological Chemistry.

[32]  A. Durandy,et al.  Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active * , 1995, The Journal of Biological Chemistry.

[33]  K. Chadee,et al.  Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. , 1995, Biochemical and biophysical research communications.

[34]  P. Libby,et al.  Cytokines Regulate Genes Involved in Atherogenesis a , 1994, Annals of the New York Academy of Sciences.

[35]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.

[36]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[37]  J. Maclouf,et al.  Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[38]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[39]  A. Ristimäki,et al.  Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. , 1994, The Journal of biological chemistry.

[40]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Mancini,et al.  Mutation of serine‐516 in human prostaglandin G/H synthase‐2 to methionine or aspirin acetylation of this residue stimulates 15‐R‐HETE synthesis , 1994, FEBS letters.

[42]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[43]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Ford-hutchinson,et al.  Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.

[45]  M. Kowala,et al.  Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor production. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Hajjar,et al.  Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  W. Stetler-Stevenson,et al.  Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. , 1992, The Journal of biological chemistry.

[49]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[50]  A. Marcus,et al.  Platelet-neutrophil-smooth muscle cell interactions: lipoxygenase-derived mono- and dihydroxy acids activate cholesteryl ester hydrolysis by the cyclic AMP dependent protein kinase cascade. , 1989, Biochemistry.

[51]  D. Levy,et al.  Identification of a phorbol ester-repressible v-src-inducible gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Mehta,et al.  Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Tanabe,et al.  Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence , 1988, FEBS letters.

[54]  J. Vane,et al.  Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Needleman,et al.  Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). , 1988, The Journal of biological chemistry.

[56]  D. Dewitt,et al.  Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Kerstein,et al.  Prostacyclin, Thromboxane A2, and Prostaglandin E2 Formation in Atherosclerotic Human Carotid Artery , 1988, Arteriosclerosis.

[58]  J. Rosenbloom,et al.  PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts. , 1987, Biochemical and biophysical research communications.

[59]  Arthur C. Guyton,et al.  Handbook of Physiology—The Cardiovascular System , 1985 .

[60]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[61]  B. Weksler,et al.  Metabolic activity of cholesteryl esters in aortic smooth muscle cells is altered by prostaglandins I2 and E2. , 1983, Journal of lipid research.

[62]  A. M. Lefer,et al.  Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. Sinzinger,et al.  PROSTACYCLIN GENERATION IN ATHEROSCLEROTIC ARTERIES , 1979, The Lancet.

[64]  S Moncada,et al.  The role of prostacyclin in vascular tissue. , 1979, Federation proceedings.

[65]  G. Milo,et al.  Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. , 1977, Science.

[66]  V. Ziboh,et al.  Inhibition of cholesterol esterification in rabbit aorta by prostaglandin E2. , 1977, Atherosclerosis.

[67]  J. Vane,et al.  An Enzyme Isolated from Arteries Transforms Prostaglandin Endoperoxides to an Unstable Substance that Inhibits Platelet Aggregation. , 1977 .

[68]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[69]  S. Yamamoto,et al.  Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. , 1976, The Journal of biological chemistry.

[70]  A. Busuttil,et al.  POLYPLOIDAL GIANT CELLS IN A LARYNGEAL BIOPSY , 1974 .

[71]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.